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Abstract
Previous work demonstrated that rats subjected to multiple withdrawals from chronic ethanol exhibit
a sensitization of anxiety-like behavior compared to animals withdrawn from treatment with an equal
but continuous amount of ethanol. This study sought to examine whether corticotropin-releasing
factor (CRF) could modulate this ethanol-withdrawal-induced anxiety-like behavior. Initially, rats
were administered with CRF (1 μg) or vehicle intraventricularly on two occasions 5 days apart while
on control diet (CD) followed by exposure to 7% ethanol diet (ED) for 5 days, with social interaction
assessed 5 h into withdrawal. Social interaction was significantly reduced in the CRF-treated animals
compared to vehicle-treated rats and vehicle-and CRF-treated rats maintained on CD, indicative that
CRF given before ethanol exposure was capable of inducing an adaptive change that sensitized
withdrawal-induced anxiety-like behavior. Next, the CRF1 receptor antagonist CRA1000 (3 mg/kg,
systemically), the CRF2 receptor antagonist antisauvagine-30 (20 μg intraventricularly), or vehicle
was injected 4 h after the ethanol was removed following the first and second cycles of chronic
ethanol exposure and the effect on the multiple-withdrawal-induced anxiety-like behavior
determined after the third withdrawal cycle. The CRF1 receptor antagonist blocked the reduced social
interaction behavior, whereas the CRF2 receptor antagonist was without effect. Similar pretreatment
with another CRF1 receptor antagonist CP-154,526 (10 mg/kg systemically) during the first and
second withdrawals also counteracted anxiety-like behavior. These findings indicate that the CRF
system and CRF1 receptors play key roles in the adaptive change responsible for the anxiety-like
behavior induced by repeated withdrawals from chronic ethanol.
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1. Introduction
Repeated ethanol exposures and withdrawals induce long-lasting adaptive changes in the brain
that are reflected by behavioral consequences (e.g., Holter et al., 1998; Malcolm et al., 2000;
McCown and Breese, 1990). In this respect, a recent investigation showed that anxiety-like
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behavior, as indexed by the social interaction test, increased in rats repeatedly withdrawn from
exposure to ethanol (Overstreet et al., 2002). Rats exposed continuously for 15 days to a diet
containing 4.5% ethanol exhibited a normal level of social interaction upon withdrawal,
indicative that the ethanol alone was not responsible for the sensitization of the anxiety-like
behavior associated with the repeated withdrawals (Overstreet et al., 2002).
Several investigators have reported alterations in the hypothalamo–pituitary–adrenal (HPA)
axis after chronic ethanol treatment (e.g., Rasmussen et al., 2000; Rivier and Lee, 2001).
Antagonists of corticotropin-releasing factor (CRF) have been reported to reduce anxiety-like
behavior observed in ethanol-withdrawn rats (Koob et al., 1998; Rassnick et al., 1993) and
attenuate foot shock-induced reinstatement of ethanol-seeking behavior (Le et al., 2000). While
CRF, by driving the HPA axis, could be a key factor in the adaptive changes associated with
chronic ethanol, a recent study demonstrated that adrenalectomy does not modulate foot shock-
induced reinstatement of ethanol-seeking behavior (Le et al., 2000). Based upon this
background, it is hypothesized that CRF contributes to the sensitized anxiety-like behavior
observed in rats repeatedly withdrawn from chronic ethanol diet (ED).
To examine the role of CRF in the multiple-withdrawal-induced sensitization, it was tested
whether central administration of CRF would substitute for the initial two withdrawals at 6
and 11 days of the multiple withdrawal protocol to induce anxiety-like behavior. Subsequently,
it was determined if selective antagonists for CRF1 and CRF2 receptors would prevent the
anxiety-like behavior seen with repeated withdrawals. These studies will support the proposed
hypothesis that CRF acting on CRF1 receptors contributes to the anxiety-like behavior observed
during repeated ethanol withdrawals.
2. Methods
2.1. Animals
Male Sprague–Dawley rats (Charles-River, Raleigh) were purchased at 40 days of age (160–
180 g). After giving 5 days to adapt to local conditions (22°C, 50% humidity, 12:12-h light–
dark cycle with lights on between 0900 and 2100 h), they were placed on a nutritionally
complete diet used previously in our laboratory (e.g., Frye et al., 1983; Moy et al., 2000;
Overstreet et al., 2002). Intakes of the liquid diet were recorded daily, and body weights were
measured weekly. These experiments were conducted in accordance with the Guide for the
Care and Use of Laboratory Animals (NRC, 1996) and were approved by the UNC Institutional
Animal Care and Use Committee.
2.2. Liquid diet
Briefly, the diet was a lactalbumin/dextrose-based, nutritionally complete diet (with
concentrations of vitamins, minerals, and other nutrients derived from ICN Research Diets).
Dextrose calories in the control diet (CD) were equated with ethanol calories in the ED (7%
w/v).
A modified pair-feeding design was used in all of the diet studies. The rats maintained on the
CD were given a volume of diet equivalent to the average volume consumed the previous day
by the rats maintained on ED. The rats were weighed at weekly intervals, and the volumes of
diet were adjusted to insure that the groups had similar body weights. In general, behavioral
assessments were conducted after 15 days of exposure to the ED, between 5 and 6 h after the
removal of the ethanol. This time point was selected on the basis of previous observations of
anxiety-like behavior in our laboratory (e.g., Knapp et al., 1998; Moy et al., 1997, 2000).
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2.3. Social interaction test
The social interaction test was first introduced by File and Hyde (1978). This test involves
placing a pair of animals in an arena and measuring the amount of time engaged in such
behaviors as grooming, sniffing, crawling over or under, and boxing; locomotor activity is
simultaneously recorded and provides a measure that is independent of social interaction (File,
1980). Social interaction has been repeatedly validated as an index of anxiety-related behavior
because it is decreased following anxiety-provoking stimuli, such as bright lights or exposure
to cat odor (File, 1980; File and Hyde, 1978), after administration of anxiogenic drugs (e.g.,
Battacharya et al., 1997; File and Lister, 1984; Guy and Gardner, 1985; Sams-Dodd, 1995) or
following withdrawal from drugs of abuse, including ethanol (Andrews et al., 1997; Costall et
al., 1990; File et al., 1989; Irvine et al., 2001; Kampov-Polevoy et al., 2000; Overstreet et al.,
2002). Conversely, social interaction can be increased by prior exposure to the test arena (File,
1980; File and Hyde, 1978) or the administration of anxiolytic drugs at doses that have little
effect on locomotor activity (Barnes et al., 1990; File, 1980; Lightowler et al., 1994).
A modification of the standard social interaction test was used to reduce the number of animals
needed for experiments. According to File (1980), the most sensitive procedure is to match up
pairs of rats that have the same treatment on the basis of their body weights and then treat the
total number of interactions by the pair as the unit of measure. However, for other experiments
where the index rat may have an implanted cannula (Gonzalez et al., 1998; Irvine et al.,
2001), an untreated dummy partner is used, and only the interactions of the index rat are
recorded. In the present studies, pairs of rats with the same treatment were placed in the arena
and the social interactions initiated by each member of the pair were recorded, thereby requiring
fewer rats. However, the 16 cannulated rats were paired with a control, untreated partner. This
design permitted a comparison of the two methods as well as provided information on whether
the anxiety-like behavior of one rat influences that of its partner. Statistical analyses of several
data sets revealed that using the data for individual rats provided the same statistical outcome
as treating the scores of the pair as a unit (Breese et al., 2003; Overstreet et al., 2003).
Furthermore, in a study of 25 pairs of rats maintained on CD and 25 on ED, the rats exhibited
essentially independent behavior, as there was no significant correlation between the scores of
the rat pairs in either group (.03 for CD, −.13 for ED). In other words, the time spent in social
interaction of one member of the pair could be quite high (>30 s), and that of the other member
quite low (< 15 s).
Experienced observers who were blind to the experimental condition carried out the social
interaction test in a square open field (60 × 60 cm, with 16 squares marked out on the floor).
The rats were unfamiliar with the open field and the lighting conditions were low (30 lx) to
generate an intermediate level of anxiety-related behavior. Rat pairs were matched on the basis
of ethanol intakes, body weights, and treatment conditions and were placed simultaneously in
the open field. During the 5-min session, line crosses (by two forepaws) and time spent in
social interaction (grooming, sniffing, following, and crawling over/under) were scored
individually for each rat (Kampov-Polevoy et al., 2000; Overstreet et al., 2002).
2.4. Intraventricular administration of CRF
After several days on CD, 30 rats were anesthetized with pentobarbital sodium, and surgery
was performed to implant guide cannulae aimed at the lateral ventricles. The rats were allowed
to recover for 1 week and then CRF (Sigma, St. Louis, MO; 1 μg; 16 rats) or artificial cerebral
spinal fluid (14 rats) was given using a 32-gauge needle. The rats were placed in the social
interaction arena 30 min after the first injection for 5 min to observe social interaction behavior
and line crosses. In about half of the rats, the pairs had the same treatment. In the other half,
an untreated control rat was paired up with a cannulated rat. The treatments were repeated 5
days later, and the following day, 14 rats (8 treated with CRF, 6 treated with vehicle) were
Overstreet et al. Page 3













exposed for 5 days to a diet containing 7% ethanol. ED was then removed and replaced with
CD, and the rats were placed by pairs in the social interaction arena 5 h later. The other subgroup
of rats, were placed in the social interaction arena at about the same time as the rats maintained
on ED (1300–1500 h), but they were paired again with an untreated control rat.
2.5. Systemic administration of CRA1000
Preliminary studies showed that 1 mg/kg CRA1000 (a gift from Taisho, Saitama, Japan), a
CRF1 receptor antagonist (Okuyama et al., 1999), would counteract the reduction in social
interaction behavior induced by withdrawal from ethanol when given 30 min before the test
(Knapp et al., in press). The present experiment sought to compare the effects of acute treatment
with CRA1000 versus treatment given during the first and second withdrawals in a three-cycle,
repeated withdrawal protocol. Rats were maintained on CD or ED. Rats on ED were exposed
to 7% ethanol for a total of 15 days, in three cycles of 5 days, with two 2-day periods of
withdrawal between Cycles 1 and 2, and 2 and 3. Some rats (n = 10) were injected with
CRA1000 (3 mg/kg ip) 4 h after the ethanol was removed during the first and second cycles,
while others were injected with the carboxymethylcellulose (CMC) vehicle at the same time.
A fourth group was also subjected to the three cycles of ethanol access and withdrawal but
were injected with CRA1000 (1 mg/kg) only 30 min before the social interaction test or 4.5 h
after the ethanol of the third cycle was removed. For all groups that had been maintained on
ethanol, CD was given throughout the periods of withdrawal.
In a separate study, the effects of pretreatment with another CRF1 receptor antagonist was
examined. Three groups of rats were either exposed to CD (n = 8) or subjected to three cycles
of 5-day exposures to ED (7%; n = 16). One of the latter groups was injected with CMC vehicle
during the first and second withdrawals, and the other group was injected with 10 mg/kg
CP-154,526 (a gift from Pfizer, Groton, CN; Seymour et al., 2003) at comparable times. Social
interaction behavior and line crossings were measured approximately 5 h after the ethanol of
the third cycle was removed.
2.6. Intraventricular administration of antisauvagine-30
After several days on CD, 18 rats were anesthetized with pentobarbital sodium, and surgery
was performed to implant guide cannulae aimed at the lateral ventricles. The rats were allowed
to recover for 1 week, and then they were subjected to three cycles of 5-day exposures to 7%
ethanol, with 2-day withdrawal periods (when CD was available) after the first and second
cycles. Rats received intraventricular injections of antisauvagine-30 (20 μg) or artificial
cerebrospinal fluid (5 μl) 4 h into the first and second withdrawals. The dose of
antisauvagine-30 was selected on the basis of published reports (Brauns et al., 2001; Radulovic
et al., 1999). The rat pairs were placed in the social interaction arena 5 h after the removal of
ethanol.
2.7. Statistical analyses
The data for social interaction were summarized as mean seconds and analyzed by one-way
ANOVAs (for the CRF, CRA1000, and CP-154,526 data) and t tests (for the anti-sauvagine-30
data). Activity was recorded as the mean number of line crosses, and the data were analyzed
by one-way ANOVAs or t tests. When the ANOVAs revealed significant group differences,
follow-up Tukey’s protected t tests were carried out to test specific pairs. Superscript letters
were used to identify the statistical relationship between groups. Groups with different letters
were significantly different according to Tukey’s test (P < .05).
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3.1. Effect of intraventricular CRF administration on withdrawal-induced anxiety-like
behavior
Rats that were initially treated with a single dose of CRF intraventricularly exhibited lower
social interaction behavior than the rats given artificial cerebrospinal fluid, confirming the
anxiogenic properties of CRF [Fig. 1; F(3,45) = 13.32, P < .001]. Interestingly, the control rats
that were used as partners for the CRF-and vehicle-treated rats (PART-C and PART-V,
respectively) spent as much time in social interaction as the vehicle-treated rats, although their
partners differed greatly in the time they spent in social interaction (Fig. 1).
Subsequently, half of the rats were pretreated intraventricularly once more with CRF or vehicle
1 day prior to a single 5-day exposure to a 7% ED, and the other half continued to have access
to CD. These multiple-CRF-treated animals exhibited a significant reduction in social
interaction during withdrawal from ED compared to vehicle-treated rats [Fig. 2; F(3,26) =
23.94, P < .001]. Also shown in Fig. 2 are data for the CRF-and vehicle-treated rats that were
maintained on CD; these animals exhibited normal social interaction behavior. Thus, CRF
treatment interacted with ethanol exposure and withdrawal to sensitize the withdrawal-induced
anxiety-like behavior. This reduction in social interaction induced by the CRF treatment was
comparable to that seen with multiple withdrawals from chronic ethanol (see Fig. 3).
In contrast to the dramatic decrease in social interaction behavior, CRF treatment slightly, but
significantly, reduced line crosses after its intraventricular administration (132 ± 8.9 for vehicle
vs. 103 ± 11 for CRF; t = 2.21, P=.035). Rats that were treated with vehicle or CRF and
maintained on CD did not differ in line crosses (91.8 ± 11.2 vs. 105.8 ± 11.0 for vehicle-and
CRF-treated, respectively; t = 0.34, P>.05). There were no differences in line crosses during
withdrawal from chronic ethanol exposure (76.5 ± 13.7 vs. 72.6 ± 10.5 for vehicle-and CRF-
treated rats, respectively; t = 0.23, P>.05). However, note that withdrawal from ethanol resulted
in decreased activity, as reported earlier (Overstreet et al., 2002). Thus, the suppression of
locomotor activity as a consequence of ethanol withdrawal does not respond to manipulations
of the CRF system, while the reduction in social interaction behavior does.
3.2. Effects of CRF1 receptor antagonists, on withdrawal-induced anxiety associated with
multiple withdrawals from chronic ethanol
Following the demonstration that CRF pretreatment sensitized ethanol withdrawal-induced
anxiety-like behavior, attention turned to determining if blockade of CRF receptors would
minimize the reduction in social interaction observed with repeated withdrawals. In Fig. 3, the
effect of the CRF1 receptor antagonist CRA1000 on social interaction behavior induced by
repeated withdrawals is illustrated. There were significant differences among the four treatment
groups [F(3,29) = 30.89, P < .001], with the group given CD exhibiting significantly more
social interaction behavior than the group given the repeated exposures to ED and treated with
vehicle (ED–VEH). Treatment with CRA1000 significantly increased social interaction
behavior in rats exposed to ED whether given into the third withdrawal or given during the
initial two withdrawals and not the final third withdrawal (ED–CRA/A and ED–CRA/P,
respectively). The group that received the CRA1000 pretreatment at 4 h into the first and second
withdrawals (ED–CRA/P) was not significantly different from the CD group—a particularly
important finding. Social interaction behaviors were not affected by acute treatment of
CRA1000 (1 mg/kg) to control rats, nor was it altered when two injections of 3 mg/kg CRA1000
was given to control rats 10 and 5 days before exposure to the social interaction arena (data
not shown; Knapp et al., in press). Therefore, CRA1000 counteracts the anxiogenic
involvement of CRF related to withdrawal from chronic ethanol but does not have a direct
anxiolytic effect by itself (see Harro et al., 2001).
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The findings for locomotor activity are summarized in Fig. 4. There were significant
differences among the groups [F(3,29) = 7.45, P < .001]. However, the reduced line crosses
observed in the ethanol-withdrawn rats were not influenced by the injections of CRA1000,
regardless of the mode of treatment (see Fig. 4). All groups that received ED were significantly
less active than the rats maintained on CD.
Importantly, another orally active nonpeptide CRF1 receptor antagonist, CP-154,526 (10 mg/
kg), administered during the first two withdrawal periods but not the third, induced just as
much time in social interaction (35.0 ± 3.6 s) as did exposure to CD (29.4 ± 4.1 s). Inasmuch
as the group repeatedly withdrawn from ethanol and given vehicle exhibited a decrease in social
interaction behavior (14.1 ± 4.1 s), these data confirm that the CRF1 receptor is involved in
the repeated-withdrawal-induced anxiety-like behavior. A one-way ANOVA [F(2,19) = 6.57,
P < .01] and subsequent Tukey’s tests confirmed that the ethanol-withdrawn, vehicle-treated
group was significantly different from the other two groups (P < .01).
3.3. Effects of antisauvagine-30, CRF2 receptor antagonist, on withdrawal-induced anxiety-
like behavior
To examine the potential role of CRF2 receptors in the withdrawal-induced anxiety,
antisauvagine-30 was tested. In contrast to the CRF1 receptor antagonist, intraventricular
pretreatment with antisauvagine-30 during the first and second withdrawals of a three-cycle
exposure to chronic ethanol did not counteract the anxiogenic behavior exhibited by repeated
ethanol withdrawals. The antisauvagine-30-treated group exhibited reduced time spent in
social interaction, similar to the time demonstrated by the vehicle-treated group in Fig. 3, and
there was no difference between the groups (11.1 ± 1.2 s of social interaction for control and
12.0 ± 1.9 s for antisauvagine-30; t = 0.39, NS). There were also no significant differences in
locomotor activity (t = 0.32, NS). The control group had 75.3 ± 7.1 line crosses and the group
treated with antisauvagine-30 had 71.3 ± 10.1. Thus, an intraventricular dose of 20 μg
antisauvagine-30 did not modify the reduced social interaction or locomotor activity associated
with repeated ethanol withdrawals.
3.4. Body weights
As indicated above, a modified pair-feeding method was used in which the volume of CD
received by the control animals was the average volume ingested on the previous day by the
rats on ED. As can be seen in Table 1, this procedure resulted in adequate control over body
weight, with no differences being observed between groups.
3.5. Ethanol intake
The average daily intakes of ethanol for the ED treatment groups in the CRA1000 study were
11.18 ± 0.37, 11.62 ± 0.34, and 11.35 ± 0.31 g/kg/day for the vehicle, acute CRA1000 and
pretreatment CRA1000 groups. The intakes of the groups in the antisauvagine-30 study were
somewhat less (10.3 ± 0.6 and 10.3 ± 0.3 g/kg/day for control and antisauvagine-30 groups,
respectively), but these intakes were not different from each other. The intakes of the groups
in the CRF study were substantially less than those in the CRA1000 study most likely because
they only had 5 days of access to ethanol. Nevertheless, the cannulated vehicle group (7.16 ±
0.33 g/kg/day) did not differ from the cannulated CRF group (7.88 ± 0.24 g/kg/day). Thus,
neither CRA1000, antisauvagine, nor CRF affected the intake of ED.
4. Discussion
Previous studies have demonstrated that restraint stress applied at weekly intervals prior to 5
days of 4.5% ED resulted in sensitization of a withdrawal-induced reduction in social
interaction behavior (Breese et al., 2003). Inasmuch as the present findings confirm that a single
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withdrawal from 7% ED does not induce anxiety-like behavior (Overstreet et al., 2002), we
were able to examine whether CRF would substitute for multiple stresses to sensitize anxiety.
It was initially demonstrated that CRF administered intraventricularly resulted in an acute
decrease in social interaction behavior 30 min later, confirming the anxiogenic effect of CRF
found in other tasks (e.g., Spina et al., 2002). Subsequently, to determine if CRF would
substitute for two stresses to sensitize withdrawal-induced anxiety-like behavior, rats on CD
were treated intraventricularly with CRF on two occasions 5 days apart to substitute for the
initial two withdrawals of the multiple withdrawal protocol. When these rats were withdrawn
from a single 5-day chronic ethanol exposure, a sensitization of anxiety was observed, to a
degree like that seen with multiple withdrawals (Figs. 2 and 3; Overstreet et al., 2002).
However, rats that were only exposed to intraventricular CRF twice (Fig. 2) or to a single 5-
day exposure to 7% ED (Fig. 2; Overstreet et al., 2002, 2003) exhibited normal social
interaction behavior. Thus, this finding supports the important role of the CRF system in
withdrawal from ethanol exposure reported by Menzaghi et al. (1994) and Knapp et al. (in
press). Of interest was that control cannulated animals did not differ from the partners (Fig. 1)
or cannulated rats that were given vehicle and were exposed to ethanol for 5 days (Fig. 2). Only
the animals given two injections of CRF and exposed to 5 days of ethanol, which by itself does
not affect social interaction behavior (Overstreet et al., 2002, 2003), exhibited a decrease in
social interaction behavior.
With confirmation that CRF is involved in the sensitization of withdrawal-induced anxiety-
like behavior arising from a single 5-day exposure to ethanol, the next approach was to
determine if antagonism of CRF receptors during the initial two withdrawals of the multiple
withdrawal protocol would antagonize the withdrawal-induced reduction in social interaction
observed with the 7% ethanol liquid diet. In this respect, the CRF1 receptor antagonists,
CRA1000 and CP-154,526, blocked the reduced social interaction associated with withdrawals
from repeated chronic ethanol exposures. This latter finding is consistent with the hypothesis
that CRF also participates in the increased anxiety-like behavior induced by repeated
withdrawals from chronic ethanol. Such a finding would be consistent with a number of other
previous reports linking anxiety-like behavior to CRF and other components of the HPA system
(Koob et al., 1998; Menzaghi et al., 1994).
A novel approach in the present investigation was administering the CRF1 receptor antagonists
during the first and second withdrawals but not during the third withdrawal to examine the role
of CRF in the repeated-withdrawal-induced anxiety. This strategy gave results comparable to
those obtained when the CRF1 receptor antagonist was given 30 min before the behavioral test
during the third withdrawal from the multiple withdrawal protocol (see Fig. 3). This outcome
suggests that an adaptive mechanism(s), passed from one withdrawal to the next, contributes
to the anxiety-like behavior associated with repeated withdrawals. Thus, CRA1000 and
CP-154,526 counteracted the adaptive changes in some system impacted by CRF during the
repeated withdrawals from ethanol. A number of earlier reports implicated CRF1 receptors in
the anxiogenic effects of CRF or stress (e.g., Heinrichs et al., 1997;Landgraf, 2001) and in the
anxiolytic effects of CRF receptor antagonists (Brauns et al., 2001;Keck et al., 2001;Radulovic
et al., 1999;Seymour et al., 2003). The present results are consistent with these reports but add
a new dimension. By pretreatment during the earlier repeated withdrawal periods, the CRF1
receptor antagonists can prevent the reduction of social interaction seen upon the final
withdrawal.
Two other recent reports have provided evidence consistent with the hypothesis that CRF1
receptors play a key role in the anxiety associated with ethanol withdrawal. Using a design
similar to that employed in this study, Breese et al. (2003) showed that the application of two
periods of restraint stress (1 h) could induce anxiety-like behavior in rats following a single 5-
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day exposure to ethanol and that the CRF1 receptor antagonist CRA1000 blocked this effect.
In a complementary study, Valdez et al. (2003) subjected rats to a brief (15-min) restraint stress
and examined anxiety-like behavior in the elevated plus maze. Only the rats that had a previous
history of alcohol exposure exhibited anxiety-like behavior; treatment with a CRF1 receptor
antagonist prevented this response.
Because antisauvagine-30, a CRF2 receptor antagonist, was without effect, the CRF1 receptor
subtype appears to be critical to the decrease in social interaction observed with withdrawal,
and the CRF2 receptor is not contributing to the sensitization of withdrawal-induced anxiety-
like behavior. However, this conclusion must remain tentative because only a single dose of
antisauvagine-30 was used in this investigation. Furthermore, the negative result in this study
does not preclude the possibility that CRF2 receptors in brain regions not reached by
intraventricular injections might participate in anxiety-like behavior because there is evidence
that urocortins, which interact selectively with CRF2 receptors, have anxiogenic effects (Spina
et al., 2002). On the other hand, Heinrichs et al. (1997) reached a conclusion similar to ours:
the CRF1 receptors are more important for anxiety-like behavior than CRF2 receptors.
Others have suggested that corticosterone may not be involved in stress-stimulated relapse in
rats because relapse still occurs in adrenalectomized rats (Le et al., 2000). Data from our
laboratory indicate that corticosterone administered instead of the initial withdrawals did not
induce a withdrawal-induced reduction in social interaction (Breese et al., 2003). Nonetheless,
several aspects concerning the role of CRF in a multiple-withdrawal-induced decrease in social
interaction require comment. For example, the present findings do not permit a conclusive
statement about the brain region(s) that may participate in the modulation of social interaction
behavior by the CRF system(s). Previous work demonstrated that the central amygdala was
involved in the anxiety induced by withdrawal from a single episode of chronic ethanol (Koob
et al., 1998; Menzaghi et al., 1994; Rassnick et al., 1993). Such work emphasizes that
extrahypothalamic sites are likely critical to the sensitized anxiety-like behavior induced by
repeated withdrawals.
Because the CRF1 receptor antagonists were effective in selectively counteracting the affective
component of the withdrawal syndrome in the rats, it is likely that they could also ameliorate
affective symptoms of withdrawal in humans (Keck and Holsboer, 2001; Kehne and De
Lombaert, 2002). Therefore, such CRF1 receptor antagonists might reduce the risk of relapse
in alcoholics because the affective symptoms experienced during ethanol withdrawal have been
implicated in the risk to relapse (Driessen et al., 2001; Sinha, 2001).
Despite the significant changes in social interaction behavior induced by prior treatment with
CRA1000 or CRF, no change in the number of line crosses was observed as a measure of
activity (Fig. 4). This finding confirms other studies indicating that social interaction and
activity, as reflected by line crosses, are controlled by independent mechanisms (Breese et al.,
2003;File, 1980;Overstreet et al., 2002,2003). In this respect, the reduction in social interaction
behavior can be sensitized by repeated ethanol withdrawals in rats maintained on a 4.5% ED
without a change in line crosses (Overstreet et al., 2002). In support of this conclusion, the
reduction in social interaction behavior associated with repeated ethanol withdrawals can be
counteracted by injections of a 5-HT2C receptor antagonist or a 5-HT1A agonist without
affecting this measure of activity (Overstreet et al., 2003).
Nonetheless, these conclusions do not preclude the possibility that reduced locomotor activity
can signify an anxiety-like state in other circumstances. Indeed, there is a long history of the
association of reduced locomotor activity with emotional behavior (Archer, 1973). The
Maudsley Reactive and Nonreactive Rats, selectively bred for differences in open field
defecation, a widely recognized index of anxiety, also differ in open-field activity (Blizard and
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Adams, 2002), as do rats selectively bred for differences in anxiety-related behavior in the
elevated plus maze (Landgraf and Wigger, 2002). Based upon these reports, it might be possible
to conclude that the reduced activity seen in ethanol-withdrawn rats is also an anxiety-like
behavior. Nevertheless, the reduction in activity is not affected by the manipulations that
counteract the reduction in social interaction (compare Fig. 3 with Fig. 4; Breese et al., 2003;
Overstreet et al., 2002, 2003).
The present study has also provided important data regarding the methodology for the social
interaction test. As indicated previously, it has been recommended that unmanipulated animals
should be paired up with the basis of treatment and body weights, whereas surgically
manipulated rats should be paired with an untreated, control rat (e.g., File, 1980; File and Seth,
2003). In this study, we examined the acute effects of CRF both when the animals had the same
treatment and when they were paired with an untreated control partner. The degree of anxiety-
like behavior was similar in the two conditions; therefore, these data were combined for the
overall analysis. So, at least for this data set, the degree of anxiety-like behavior observed in
one rat is not influenced by the degree of anxiety-like behavior exhibited by its partner. By the
same token, the partners of the vehicle-and CRF-treated rats were not different, indicating that
the behaviors of normal rats are also not influenced by the degree of anxiety-like behavior
exhibited by their partner. These current data also support the approach we have used to analyze
social interaction behavior, using the data from individual animals (see Breese et al., 2003;
Overstreet et al., 2003).
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Effects of acute intraventricular injection of CRF or vehicle on social interaction behavior. One
week after rats were cannulated into the cerebral ventricles, the rats were infused with 1 μg
CRF (n = 16) or artificial cerebrospinal fluid (n = 14). Some pairs of rats with the same treatment
were placed in the open field arena 30 min later for the measurement of social interaction
behavior. Other rats (8 of each) were placed in the open field with untreated control rats as
their partners. CRF-and vehicle-treated rats exhibited similar levels of social interaction
behavior in the two conditions, so the data were combined. The data represent the mean seconds
± S.E.M. of time spent in social interaction. The CRF-treated group (CRF–ICV) spent
significantly less time in social interaction than either the vehicle-treated group (VEH–ICV)
or the two partner groups (PART-C; PART-V), according to Tukey’s protected t tests (P < .
01).
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Effects of prior treatment with CRF or vehicle on social interaction behavior in rats maintained
on CD or withdrawn from a 5-day exposure to 7% ethanol. Artificial cerebrospinal fluid or
CRF (1 μg) were infused 1 and 6 days before exposure to 5 consecutive days of 7% ED. The
social interaction test was carried out 5 h after withdrawal from ethanol or at the same time in
the afternoon 5 days after the last CRF treatment in the rats maintained on CD. The data
represent the mean seconds ± S.E.M. of time spent in social interaction. The group pretreated
with CRF and subsequently exposed to ethanol (ED – CRF) engaged in significantly less social
interaction behavior than the group pretreated with vehicle and exposed to ethanol (ED–VEH)
or the groups maintained throughout on CD (CD–CRF; CD–VEH), according to Tukey’s
protected t tests (P < .01).
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Effects of CRA1000 on social interaction behavior of rats subjected to repeated withdrawals
from ethanol. Rats were exposed to CD throughout (n = 8) or three cycles of 5 days of an ED
(7% w/v). The rats were maintained on CD during the 2 days of withdrawal between the first
and second, and the second and third cycles, and between ethanol withdrawal and behavior
testing after the third cycle. One group was injected with CMC vehicle at 4 h into the first and
second withdrawal (ED –VEH); one was pretreated with 3 mg/kg CRA1000 at the same times
(ED–CRA/P); the final group was injected acutely with 1 mg/kg CRA1000 30 min before the
social interaction test on the third withdrawal, 4.5 h after the ethanol was removed (ED–CRA/
A). The other groups exposed to ED were also tested in the social interaction arena 5 h after
removal of ethanol. The data represent the mean seconds ± S.E.M. of time spent in social
interaction for eight rats per group. A one-way ANOVA revealed significant group differences
(P < .01). Groups with different letters are significantly different according to Tukey’s test
(P < .01).
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Effects of CRA1000 on line crosses of rats subjected to repeated withdrawals from ethanol.
See legend of Fig. 3 for description of procedure. The data represent the mean ± S.E.M. line
crosses for eight rats per group. A one-way ANOVA revealed significant group differences
(P < .001). Groups with different letters are significantly different according to Tukey’s test
(P < .01).
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Table 1
Body weights (g) of rats used in the studies
Treatment group (n) Initial weight Final weight
Experiment 1
Cannulated vehicle (6) 382.8 ± 13.9 397.3 ± 5.9
Cannulated CRF (8) 386.8 ± 17.1 393.7 ± 14.5
Experiment 2
CD (8) 195.9 ± 3.2 296.4 ± 3.2
ED–VEH (12) 198.1 ± 1.7 292.2 ± 4.9
ED–CRA/A (10) 195.7 ± 2.6 297.2 ± 5.4
ED–CRA/P (10) 201.1 ± 2.3 306.3 ± 10.5
Experiment 3
Cannulated vehicle (8) 351.1 ± 7.7 356.8 ± 6.4
Antisauvagine-30 (10) 358.3 ± 8.6 372.2 ± 9.6
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